Algorithms for the interpretation of HIV-1 genotypic drug resistance information

被引:44
作者
Vercauteren, Jurgen [1 ]
Vandamme, Anne-Mieke [1 ]
机构
[1] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium
关键词
HIV; drug resistance; interpretation system; algorithm; genotype; phenotype;
D O I
10.1016/j.antiviral.2006.05.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drug resistance testing has proven its use to guide treatment decisions in HIV-1 infected patients. Genotyping is the preferred technique for clinical drug resistance testing. Many factors complicate the interpretation of mutations towards therapy response, such that an interpretation system is necessary to help the clinical virologist. No consensus interpretation exists to date and experts often have quite different opinions. As a result, several algorithms for the interpretation of HIV-1 genotypic drug resistance information have been designed. Clinical evaluation of their genotypic interpretation is not always straightforward. We describe a few publicly available systems and their clinical evaluation. We also stress that in addition to drug resistance, for effective management of HIV infection the clinician needs to take into account all potential causes of treatment failure. Successful therapy heavily relies on the expertise of the clinician. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:335 / 342
页数:8
相关论文
共 57 条
  • [1] Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G
    Abecasis, AB
    Deforche, K
    Snoeck, J
    Bacheler, LT
    McKenna, P
    Carvalho, AP
    Gomes, P
    Camacho, RJ
    Vandamme, AM
    [J]. AIDS, 2005, 19 (16) : 1799 - 1806
  • [2] ABECASIS AB, IN PRESS ANTIVIR THE
  • [3] Computational methods for the design of effective therapies against drug resistant HIV strains
    Beerenwinkel, N
    Sing, T
    Lengauer, T
    Rahnenführer, J
    Roomp, K
    Savenkov, I
    Fischer, R
    Hoffmann, D
    Selbig, J
    Korn, K
    Walter, H
    Berg, T
    Braun, P
    Fätkenheuer, G
    Oette, M
    Rockstroh, J
    Kupfer, B
    Kaiser, R
    Däumer, M
    [J]. BIOINFORMATICS, 2005, 21 (21) : 3943 - 3950
  • [4] Beerenwinkel N, 2002, ANTIVIR THER, V7, pS98
  • [5] Geno2pheno:: estimating phenotypic drug resistance from HIV-1 genotypes
    Beerenwinkel, N
    Däumer, M
    Oette, M
    Korn, K
    Hoffmann, D
    Kaiser, R
    Lengauer, T
    Selbig, J
    Walter, H
    [J]. NUCLEIC ACIDS RESEARCH, 2003, 31 (13) : 3850 - 3855
  • [6] Brun-Vézinet F, 2003, AIDS, V17, P1795, DOI [10.1097/00002030-200308150-00008, 10.1097/01.aids.0000072669.21517.db]
  • [7] Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy
    Buckheit, RW
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2004, 13 (08) : 933 - 958
  • [8] Stability of transmitted drug-resistant HIV-1 species
    Cane, PA
    [J]. CURRENT OPINION IN INFECTIOUS DISEASES, 2005, 18 (06) : 537 - 542
  • [9] Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA)
    Cingolani, A
    Antinori, A
    Rizzo, MG
    Murri, R
    Ammassari, A
    Baldini, F
    Di Giambenedetto, S
    Cauda, R
    De Luca, A
    [J]. AIDS, 2002, 16 (03) : 369 - 379
  • [10] A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy
    Cohen, CJ
    Hunt, S
    Sension, M
    Farthing, C
    Conant, M
    Jacobson, S
    Nadler, J
    Verbiest, W
    Hertogs, K
    Ames, M
    Rinehart, AR
    Graham, NM
    [J]. AIDS, 2002, 16 (04) : 579 - 588